Carboxamide spirohydantoin CGRP receptor antagonists

1. A compound of the formula I:

wherein:

B is a selected from the group consisting of:

C 3-10 cycloalkyl, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl, azepinyl, azetidinyl, benzimidazolyl, benzisoxazolyl, benzofuranyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, benzopyrazolyl, benzotriazolyl, chromanyl, cinnolinyl, dibenzofuranyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, furanyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, morpholinyl, naphthyridinyl, oxazepinyl, oxadiazolyl, 2-oxoazepinyl, 4-oxonaphthyridinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxopyridyl, 2-oxoquinolinyl, piperidinyl, piperazinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuranyl, tetrahydrofuryl, tetrahydroimidazopyridinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazepinyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, and triazolyl,

where B is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R 1 , R 2 , R 3a and R 3b , wherein

R 1 , R 2 , R 3a and R 3b are independently selected from:

(1) —C 1-6 alkyl, which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) —O—C 1-6 alkyl,

(d) —C 3-6 cycloalkyl,

(e) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, or morpholinyl,

which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy,

(v) trifluoromethyl, and

(vi) —OCF 3 ,

(f) —CO 2 R 9 , wherein R 9 is independently selected from:

(i) hydrogen,

(ii) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(iii) —C 5-6 cycloalkyl,

(iv) benzyl, and

(v) phenyl,

(g) —NR 10 R 11 , wherein R 10 and R 11 are independently selected from:

(i) hydrogen,

(ii) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(iii) —C 5-6 cycloalkyl,

(iv) benzyl,

(v) phenyl,

(vi) —COR 9 , and

(vii) —SO 2 R 12 ,

(h) —SO 2 R 12 , wherein R 12 is independently selected from:

(i) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(ii) —C 5-6 cycloakyl,

(iii) benzyl, and

(iv) phenyl,

(i) —CONR 10a R 11a , wherein R 10a and R 11a are independently selected from:

(i) hydrogen,

(ii) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(iii) —C 5-6 cycloalkyl,

(iv) benzyl,

(v) phenyl,

or where R 10a and R 11a may be joined together to form a ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

 (I) —C 1-6 alkyl

 (II) —O—C 1-6 alkyl

 (III) halo

 (IV) hydroxy

 (V) phenyl, and

 (VI) benzyl,

(j) trifluoromethyl,

(k) —OCO 2 R 9 ,

(l) —(NR 10a )CO 2 R 9 ,

(m) —O(CO)NR 10a R 11a , and

(n) —(NR 9 )(CO)NR 10a R 11a ,

(2) —C 3-6 cycloalkyl, which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) —O—C 1-6 alkyl,

(d) trifluoromethyl,

(e) phenyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy, and

(v) trifluoromethyl,

(3) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, pyridazinyl, pyrrolidinyl, azetidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, tetrazolyl, azepinyl, benzimidazolyl, benzopyranyl, benzofuryl, benzothiazolyl, benzoxazolyl, chromanyl, furyl, imidazolidinyl, imidazolinyl, indolinyl, indolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, isoindolinyl, tetrahydroisoquinolinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, pyrazolidinyl, pyrazolyl, pyrrolyl, quinazolinyl, tetrahydrofuryl, thiazolinyl, purinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, 1,3-dioxolanyl, oxadiazolyl, piperidinyl and morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(b) halo,

(c) hydroxy,

(d) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(e) —C 3-6 cycloalkyl,

(f) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, or morpholinyl,

which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy, and

(v) trifluoromethyl,

(g) —CO 2 R 9 ,

(h) —NR 10 R 11 ,

(i) —CONR 10 R 11 ,

(j) —SO 2 R 12 , and

(k) oxo,

(4) halo,

(5) oxo,

(6) hydroxy,

(7) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1-5 halo,

(8) —CN,

(9) —CO 2 R 9 ,

(10) —NR 10 R 11 ,

(11) —SO 2 R 12 ,

(12) —CONR 10a R 11a ,

(13) —OCO 2 R 9 ,

(14) —(NR 10a )CO 2 R 9 ,

(15) —O(CO)NR 10a R 11a , and

(16) —(NR 9 )(CO)NR 10a R 11a ;

or where R 3a and R 3b and the atom(s) to which they are attached may be joined together to form a ring selected from cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl, cyclohexyl, phenyl, naphthyl, thienyl, thiazolyl, thiazolinyl, oxazolyl, oxazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrrolinyl, morpholinyl, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridyl, furanyl, dihydrofuranyl, dihydropyranyl or piperazinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) —C 1-6 alkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:

(i) halo,

(ii) hydroxy,

(iii) —O—C 1-6 alkyl,

(iv) —C 3-6 cycloalkyl,

(v) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperidinyl, piperazinyl, pyrrolidinyl, thienyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

 (I) —C 1-6 alkyl,

 (II) —O—C 1-6 alkyl,

 (III) halo,

 (IV) hydroxy,

 (V) trifluoromethyl, and

 (VI) —OCF 3 ,

(vi) —CO 2 R 9 ,

(vii) —NR 10 R 11 ,

(viii) —SO 2 R 12 ,

(ix) —CONR 10a R 11a , and

(x) —(NR 10a )CO 2 R 9 ,

(b) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, pyridazinyl, pyrrolidinyl, azetidinyl, piperidinyl and morpholinyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(ii) halo,

(iii) hydroxy,

(iv) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro, and

(v) —C 3-6 cycloalkyl,

(c) halo,

(d) —SO 2 R 12 ,

(e) hydroxy,

(f) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1-5 halo,

(g) —CN,

(h) —COR 12 ,

(i) —NR 10 R 11 ,

(j) —CONR 10a R 11a ,

(k) —CO 2 R 9 ,

(l) —(NR 10a )CO 2 R 9 ,

(m) —O(CO)NR 10a R 11a ,

(n) —(NR 9 )(CO)NR 10a R 11a , and

(o) oxo;

A 1 and A 2 are independently selected from:

(1) a bond,

(2) —CR 13 R 14 —, wherein R 13 and R 14 are independently selected from:

(a) hydrogen,

(b) C 1-6 alkyl, which is unsubstituted or substituted with 1-5 substituents wherein the substituents are independently selected from:

(i) halo,

(ii) hydroxy,

(iii) —NR 10 R 11 ,

(iv) —CONR 10a R 11a ,

(v) —CO 2 R 9 ,

(c) phenyl, which is unsubstituted or substituted with 1-3 substituents wherein the substituents are independently selected from:

(i) C 1-4 alkyl,

(ii) hydroxy,

(iii) halo,

(d) —CONR 10 —(C 1-6 alkyl)-NR 15 R 16 , wherein R 15 and R 16 are independently selected from:

(i) hydrogen,

(ii) —C 1-6 alkyl,

(iii) —COR 9 , and

(iv) —CO 2 R 9 ,

(e) —CO 2 R 9 ,

(f) —CONR 10a R 11a , and

(g) hydroxy, and

(3) —CH 2 CR 13 R 14 —,

or wherein one of A 1 and A 2 is absent;

R 4 is selected from:

(1) hydrogen,

(2) C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(3) C 5-6 cycloalkyl,

(4) benzyl, and

(5) phenyl,

or where R 4 may be joined to B to form a ring selected from piperidinyl, pyrrolidinyl, piperazinyl, azetidinyl, azepinyl or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy,

(v) phenyl, and

(vi) benzyl;

R 5a , R 5b and R 5c are independently selected from:

(1) hydrogen,

(2) C 1-6 alkyl,

(3) —O—C 1-6 alkyl,

(4) —OCF 3 ,

(5) trifluoromethyl,

(6) halo,

(7) hydroxy, and

(8) —CN;

R 6 is selected from:

(1) hydrogen,

(2) —C 1-6 alkyl or —C 3-6 cycloalkyl which are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) —O—C 1-6 alkyl,

(d) —C 3-6 cycloalkyl,

(e) phenyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(i) —C 1-6 alkyl,

(ii) —O—C 1-6 alkyl,

(iii) halo,

(iv) hydroxy, and

(v) trifluoromethyl,

(f) —CO 2 R 9 ,

(g) —NR 10 R 11 ,

(h) —CONR 10 R 11 ,

(i) —SO 2 R 12 , and

(j) trifluoromethyl,

(3) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyrimidinyl, pyrazinyl, thienyl, or morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) —C 1-6 alkyl,

(b) —O—C 1-6 alkyl,

(c) halo,

(d) hydroxy, and

(e) trifluoromethyl;

m is 1 or 2;

n is 1 or 2;

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

2. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

3. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

4. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

5. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

6. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

7. The compound of claim 1 of the formula:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

8. The compound of claim 1 wherein B is selected from the group consisting of:

C 3-10 cycloalkyl, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, azepinyl, benzimidazolyl, imidazolyl, imidazolinyl, imidazolidinyl, indolinyl, indolyl, isoquinolinyl, morpholinyl, naphthyridinyl, oxazepinyl, 2-oxoazepinyl, 2-oxopyrrolidinyl, 2-oxopyridyl, piperazinyl, piperidinyl, pyrazinyl, pyridinyl, pyridyl, pyrimidyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuranyl, thiazolyl, and thiazolinyl,

where B is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R 1 , R 2 , R 3a and R 3b .

9. The compound of claim 1 wherein R 1 , R 2 , R 3a and R 3b are independently selected from:

(1) —C 1-6 alkyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) halo,

(b) —C 3-6 cycloalkyl, and

(c) phenyl,

(2) phenyl or heterocycle, wherein heterocycle is selected from: pyridyl, pyridinyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolinyl, imidazolidinyl and morpholinyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:

(a) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(b) halo, and

(c) oxo,

(3) halo,

(4) oxo,

(5) hydroxy,

(6) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1-5 halo,

(7) —CN, and

(8) —SO 2 R 12 ,

or where R 3a and R 3b and the atom(s) to which they are attached may be joined together to form a ring selected from phenyl, thiazolinyl, imidazolyl, imidazolinyl, pyridyl, morpholinyl, pyrrolidinyl, piperidinyl, and tetrahydrofuranyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) —C 1-6 alkyl,

(b) halo,

(c) —CF 3 ,

(d) hydroxy,

(e) —O—C 1-6 alkyl, and

(f) oxo.

10. The compound of claim 1 wherein R 4 is selected from: hydrogen and —C 1-6 alkyl, which is unsubstituted or substituted with fluoro.

11. The compound of claim 1 wherein R 4 may be joined to B to form a piperidinyl ring.

12. The compound of claim 1 wherein R 5a , R 5b and R 5c are independently selected from hydrogen, C 1-6 alkyl and halo.

13. The compound of claim 1 wherein R 6 is hydrogen or methyl.

14. The compound of claim 1 wherein R 13 and R 14 are independently selected from:

(a) hydrogen,

(b) phenyl,

(c) —CONR 10 —(C 1-6 alkyl)-NR 15 R 16 , wherein R 15 and R 16 are independently selected from:

(i) hydrogen,

(ii) —C 1-6 alkyl,

(iv) —CO 2 R 9 , and

(d) —CO 2 R 9 .

15. A compound selected from:

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

16. A pharmaceutical composition which comprises an inert carrier and the compound of claim 1 .

17. A method of treating migraine headaches or cluster headaches comprising the administration to a person in need thereof of a therapeutically effective amount of a compound of claim 1 .